A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

NCT00135343 Phase 3 COMPLETED

The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir, ritonavir and efavirenz, using two different doses of atazanavir.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 3
Status	COMPLETED
Enrolment	60
Start date	2004-04
Completion	2005-10

Conditions

• HIV Infections

Interventions

• Atazanvir/ritonavir + efavirenz
• Atazanvir/ritonavir + efavirenz

Primary outcomes

• Mean percent change from baseline in fasting plasma triglycerides at Week 8

Countries

United States